Page 174 - 2020_01-Haematologica-web

S. Kayser et al.
disease. Of those, six patients are still in CR after a median follow up of 66.5 months (range: 11.8-110.8 months) and two patients achieved CR2 after relapse and are still in CR, whereas seven patients died (transplant-related mortality, n=4; refractory AML after relapse, n=2; pulmonary embolism 7.9 years after transplant, n=1).
Allogeneic hematopoietic stem cell transplantation after relapse
Three patients proceeded to allo-HCT with active dis- ease after relapse and all of these patients died. Causes of death included infection after 56 days in one and GvHD
15 days after transplant in another patient. One patient died due to refractory AML after relapse.
Characteristics of patients undergoing allogeneic hematopoietic stem cell transplantation
Overall, an allo-HCT was performed in 117 of the 178 patients (66%), either in CR1 (n=89) or CR2 (n=10), with refractory disease (n=15) or after relapse (n=3) with no differences in baseline characteristics between groups (Table 1).
The majority of patients (n=76) received myeloablative conditioning, including total body irradiation (TBI) in 39
Table 1. Baseline characteristics of patients with acute myeloid leukemia and t(6;9)(p22;q34).
All patients (n=178)
46 (16-76) 96 (54) 16.6 (0.5-274) 12
8.6 (3.2-14.2) 29
53 (7-451) 21
60 (7-100) 22
11 (6) 4 (2) 13 (7)
De novo AML
s-AML
t-AML 4(2) 3(3) - MDS 5(3) 1(1) 2(11)
FLT3-ITD
n (%) 79 (62) 43 (57) 9 (60) Missing 51 25 3
FLT3-TKD
Missing 102 48 9
allo; allogeneic; AML: acute myeloid leukemia; BM: bone marrow; CR: complete remission; FLT3: fms-related tyrosine kinase 3; HCT: hematopoietic cell transplantation; ITD: internal tandem duplication; s-AML: AML after previous myelodysplastic syndrome / myeloproliferative neoplasm; t-AML: therapy-related AML; TKD: tyrosine kinase domain; WBC: white blood cell count. *Within a complex karyotype characterized by gains only (n=5). **Within a complex karyotype characterized by losses and unbalanced translo- cations. +Other than +8/+13/nullisomy X/Y. Results may not add-up to 100 due to rounding.
Median age (years) (Range)
Male gender, n (%)
Median WBC, x109/L (Range)
Missing
Median hemoglobin, g/dL (Range)
Missing
Median platelets, x109/L (Range)
Missing
Median BM blasts, % (Range)
Missing
Cytogenetics, n (%)
Other complex** Nullisomy X/Y Other+
Disease type, n (%)
Subset of patients undergoing allo-HCT in CR (n=99)
43 (16-71) 57 (58) 13.1 (0.5-274) 8
8.6 (3.2-14.2) 18
53 (7-451) 13
55 (10-100) 12
Subset of patients undergoing allo-HCT with active disease/ relapse (n=18)
46 (19-69) 9 (50) 16.3 (1.5-200.4) 1
9 (4.6-13.1) 2
59 (10-229) 2
60 (7-90)
1
14 (78)
1 (6) 2 (11) 1 (6)
As sole aberration Including +13*
140 (79) 10 (6)
79 (80) 6 (6)
- Sole+13 1 - - +8,+13 2 1 -
6 (6)
-
7 (7)
157 (88) 12 (7)
88 (89) 7 (7)
15 (83) 1 (6)
n(%) 4(5) 4(8) -
164
haematologica | 2020; 105(1)